GlassScriptPhysician profile
Rajesh Gupta
NPI 1750368239
$1,776.41
in general payments reported to CMS, 2019-2025
21 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $65.82 · 2021: $79.47 · 2022: $282 · 2023: $624 · 2024: $312 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $338.12 | 2021-2024 | Zeposia |
| Abbvie INC. | $299.57 | 2023-2025 | |
| Pfizer INC. | $233.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.44 | 2019-2025 | Xifaxan |
| Ucb, INC. | $146.27 | 2019-2023 | |
| Redhill Biopharma INC. | $111.03 | 2022 | |
| Janssen Biotech, INC. | $82.71 | 2020-2024 | Stelara |
| Boston Scientific Corporation | $74.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.03 | 2019-2023 | Entyvio |
| Ferring Pharmaceuticals INC. | $48.01 | 2019-2023 | Rebyota |
| Abiomed | $33.80 | 2021 | |
| Madrigal Pharmaceuticals | $17.83 | 2025 | Rezdiffra |
| Olympus America INC. | $17.81 | 2023 | Endoclot Phs |
| Ardelyx, INC. | $17.50 | 2025 | Ibsrela |
| Echosens North America, INC. | $17.42 | 2025 | Fibroscan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $17.02 | 2021 | |
| Aimmune Therapeutics, INC. | $17.02 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.25 | 2023 | Voquezna |
| Fresenius Kabi USA, LLC | $13.48 | 2024 | Idacio |
| Shire North American Group INC | $13.32 | 2019 | |
| Qol Medical, LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.